Analysts’ Downgrades for August, 29th (EDPFY, ENQUF, FINL, HIK, KITE, LOXO, NKE, NTLA, PHGUF, PRAH)

Analysts’ downgrades for Tuesday, August 29th:

Energias de Portugal (OTCMKTS:EDPFY) was downgraded by analysts at Berenberg Bank from a buy rating to a hold rating.

Enquest PLC (NASDAQ:ENQUF) was downgraded by analysts at Jefferies Group LLC from a buy rating to a hold rating.

The Finish Line (NASDAQ:FINL) was downgraded by analysts at FBR & Co from a buy rating to a hold rating.

The Finish Line (NASDAQ:FINL) was downgraded by analysts at Citigroup Inc. from a neutral rating to a sell rating.

The Finish Line (NASDAQ:FINL) was downgraded by analysts at Jefferies Group LLC from a buy rating to a hold rating. The firm currently has $13.00 target price on the stock, down from their previous target price of $17.00.

The Finish Line (NASDAQ:FINL) was downgraded by analysts at Buckingham Research from a neutral rating to an underperform rating.

Hikma Pharmaceuticals Plc (LON:HIK) was downgraded by analysts at Stifel Nicolaus to a hold rating. Stifel Nicolaus currently has GBX 1,320 ($17.07) target price on the stock, down from their previous target price of GBX 2,300 ($29.75).

Kite Pharma (NASDAQ:KITE) was downgraded by analysts at Canaccord Genuity from a buy rating to a hold rating.

Loxo Oncology (NASDAQ:LOXO) was downgraded by analysts at JMP Securities from an outperform rating to a market perform rating. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Nike (NYSE:NKE) was downgraded by analysts at Jefferies Group LLC to a buy rating.

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Chardan Capital from a buy rating to a neutral rating. They currently have $20.00 price target on the stock.

Pharming Group (NASDAQ:PHGUF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands. “

PRA Health Sciences (NASDAQ:PRAH) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina. “

Purplebricks Group (NASDAQ:PRPPF) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Purplebricks Group Plc offer web-based real estate services. The Company provides property search, reviews, valuation, consulting and listings services. Purplebricks Group Plc is headquartered in Solihull, the United Kingdom. “

ProQR Therapeutics N.V. (NASDAQ:PRQR) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

Party City Holdco (NYSE:PRTY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Party City Holdco Inc. is involved in designs, manufactures, contracts for manufacture and distributes party goods, including paper and plastic tableware, metallic and latex balloons, Halloween and other costumes, accessories, novelties, gifts and stationery. It also operates specialty retail party supply stores primarily in the United States and Canada. Party City Holdco Inc. is based in Elmsford, New York. “

Randstad Hldgs Nv (NASDAQ:RANJY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Randstad Holding NV operates as a global provider of HR services including temporary staffing, permanent placement, recruitment of middle and senior managers, on site consulting, seconded specialists and specialized HR services. Its staffing segment service comprise of temporary staffing, permanent placement and (high-volume) specialties; the inhouse service segment specializes in the provision of high-volume, skilled flexible labor; aimed at improving labor flexibility, retention, productivity and efficiency while HR solutions & managed services segment offers a comprehensive range of HR project management, HR management and HR consultancy services. The Company also recruits supervisors, managers, professionals, interim specialists and consultants with professional qualifications for middle and senior management positions. Randstad Holding NV is headquartered in Diemen, the Netherlands. “

Ra Pharmctl (NASDAQ:RARX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Rakuten Inc (NASDAQ:RKUNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Rakuten, Inc. engages in the internet services business. Its operating segments consist of Internet Services, FinTech and Others. Internet Services segment manages e-commerce, online cash-back, travel booking, and portal and digital content sites. FinTech segment provides services over the internet related to banking and securities, credit cards, life insurance and electronic money. Others segment includes the provision of messaging and communication services and management of a Japanese professional baseball team. Rakuten, Inc. is headquartered in Tokyo, Japan. “

TriplePoint Venture Growth BDC Corp. (NYSE:TPVG) was downgraded by analysts at Compass Point from a buy rating to a neutral rating.

Tullow Oil Plc (NASDAQ:TUWOY) was downgraded by analysts at Jefferies Group LLC from a buy rating to a hold rating.